Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes

Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes

Competing interests
R.N. reports receiving grants from Helmsley Charitable Trust, Dexcom and Insulet, personal fees and others from DreaMed Diabetes Ltd, personal fees from Novo Nordisk and Eli Lilly and grants from Medtronic. In addition, R.N. owns DreaMed Diabetes Ltd stock and has a patent licensed by DreaMed Diabetes Ltd. T.B. reports receiving grants and personal fees from Novo Nordisk, Medtronic and Abbott, personal fees from Eli Lilly, Sanofi, Indigo, Roche, AstraZeneca and Dexcom and grants from Glusense and Zealandpharma. In addition, T.B. owns DreaMed Diabetes Ltd stocks. L.M.L. reports receiving grants from Helmsley Charitable Trust and personal fees from Eli Lilly, Novo Nordisk, Sanofi, Convatec, Roche, Insulogic, Dexcom, Insulet, AstraZeneca, Boehringer Ingelheim and Janssen. S.A.W. reports receiving grants from Helmsley Charitable Trust, grants and personal fees from Medtronic and personal fees from Insulet, Tandem, Eli Lilly, Sanofi and Zealand. T.D. reports receiving grants and personal fees from AstraZeneca, DexCom, Boehringer, Novo Nordisk, Medtronic, Sanofi, Eli Lilly and Insulet. In addition, T.D. owns DreaMed Diabetes Ltd stocks. M.P. reports receiving grants from Helmsley Charitable Trust, Dexcom and Insulet, personal fees and others from DreaMed Diabetes Ltd, grants and personal fees from Medtronic and Novo Nordisk, grants from Roche, Eli Lilly and Sanof, grants from Lexicon and OPKO and personal fees from RSP Systems and Qulab Medical. In addition, M.P. owns DreaMed Diabetes Ltd stock and has a patent licensed by DreaMed Diabetes Ltd. R.H.S., D.S. and K.D. declare no competing interests.

Via Source link